Land: Europeiska unionen
Språk: engelska
Källa: EMA (European Medicines Agency)
bevacizumab
Mylan IRE Healthcare Limited
L01XC07
bevacizumab
Antineoplastic agents
Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix.
Withdrawn
59 B. PACKAGE LEAFLET Medicinal product no longer authorised 60 PACKAGE LEAFLET: INFORMATION FOR THE USER LEXTEMY 25 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION bevacizumab This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects. READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Lextemy is and what it is used for 2. What you need to know before you are given Lextemy 3. How Lextemy is given 4. Possible side effects 5. How to store Lextemy 6. Contents of the pack and other information 1. WHAT LEXTEMY IS AND WHAT IT IS USED FOR Lextemy contains the active substance bevacizumab, which is a humanised monoclonal antibody (a type of protein that is normally made by the immune system to help defend the body from infection and cancer). Bevacizumab binds selectively to a protein called human vascular endothelial growth factor (VEGF), which is found on the lining of blood and lymph vessels in the body. The VEGF protein causes blood vessels to grow within tumours, these blood vessels provide the tumour with nutrients and oxygen. Once bevacizumab is bound to VEGF, tumour growth is prevented by blocking the growth of the blood vessels which provide the nutrients and oxygen to the tumour. Lextemy is a medicine used for the treatment of adult patients with advanced cancer in the large bowel, i.e., in the colon or rectum. Lextemy will be administered in combination with chemotherapy treatment containing a fluoropyrimidine medicine. Lextemy is also used for the treatment of adult pa Läs hela dokumentet
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Medicinal product no longer authorised 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Lextemy 25 mg/mL concentrate for solution for infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL of concentrate contains 25 mg of bevacizumab*. Each 4 mL vial contains 100 mg of bevacizumab. Each 16 mL vial contains 400 mg of bevacizumab. For dilution and other handling recommendations, see section 6.6. *Bevacizumab is a recombinant humanised monoclonal antibody produced by DNA technology in Chinese Hamster Ovary cells. Excipient(s) with known effect Each 4 mL vial contains 4.196 mg of sodium. Each 16 mL vial contains 16.784 mg of sodium. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Concentrate for solution for infusion (sterile concentrate). Clear to slightly opalescent, colourless to pale brown liquid with a pH of 5.70 to 6.40, an osmolality of 0.251 - 0.311 Osmol/kg and free of visible particles. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Lextemy in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. Lextemy in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1. Lextemy in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline-containing regimens in the adjuvant setting within the last 12 months should Läs hela dokumentet